Kymera Therapeutics

Gilead pays Kymera $45M for preclinical protein degrader

Gilead tucked another candidate into a pipeline bulging from a recent deal flurry, paying $45 million for Kymera’s anticancer molecular glue degrader.

Nick Paul Taylor Apr 9, 2026 8:45am

positive negative up down good bad mixed

Kymera suffers Sanofi setback but secures $750M Gilead deal

Jun 25, 2025 9:31am

pivot change turnaround direction walk away

Kymera pivots to immunology, seeks partners for cancer assets

Nov 1, 2024 11:46am

try again dead end retry restart again second attempt blocked new plan

Kymera cuts lymphoma med that performed as expected in phase 1

Nov 2, 2023 9:30am

Former Arena CEO takes over new RNA biotech—Chutes & Ladders

May 26, 2023 9:30am

Sanofi backs protein degrader after glimpse of clinical efficacy

Dec 14, 2022 7:00am